A

Anne Arundel Medical Center | Anne Arundel Research Institute

Research site
(Unclaimed)
Location
2001 Medical Parkway Belcher Pavilion Suite 203, Annapolis, Maryland, United States of America
Site insights

Top conditions

Breast Cancer (31 trials)

Carcinoma (19 trials)

Lung Cancer (17 trials)

Non-Small-Cell Lung Carcinoma (13 trials)

Recurrence (7 trials)

Top treatments

Paclitaxel
Carboplatin
Bevacizumab
Temozolomide
Exemestane
Cisplatin
Crizotinib
Docetaxel
Palbociclib
Capivasertib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

5 of 111
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (MAGNIFY)

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is a...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib...

Active, not recruiting
Breast Cancer
Drug: Standard Adjuvant Endocrine Therapy
Drug: Palbociclib

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior t...

Active, not recruiting
Estrogen Receptor Positive Breast Cancer
HER-2 Positive Breast Cancer
Drug: palbociclib
Drug: trastuzumab

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Enrolling
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab B)

Trial sponsors

National Cancer Institute (NCI) logo

National Cancer Institute (NCI) (21 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems